Last reviewed · How we verify
human papillomavirus vaccine, recombinant — Competitive Intelligence Brief
marketed
Biologic
Live · refreshed every 30 min
Target snapshot
human papillomavirus vaccine, recombinant (human papillomavirus vaccine, recombinant) — Louisiana State University Health Sciences Center in New Orleans.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| human papillomavirus vaccine, recombinant TARGET | human papillomavirus vaccine, recombinant | Louisiana State University Health Sciences Center in New Orleans | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- human papillomavirus vaccine, recombinant CI watch — RSS
- human papillomavirus vaccine, recombinant CI watch — Atom
- human papillomavirus vaccine, recombinant CI watch — JSON
- human papillomavirus vaccine, recombinant alone — RSS
Cite this brief
Drug Landscape (2026). human papillomavirus vaccine, recombinant — Competitive Intelligence Brief. https://druglandscape.com/ci/human-papillomavirus-vaccine-recombinant. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab